JP2013173782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013173782A5 JP2013173782A5 JP2013097487A JP2013097487A JP2013173782A5 JP 2013173782 A5 JP2013173782 A5 JP 2013173782A5 JP 2013097487 A JP2013097487 A JP 2013097487A JP 2013097487 A JP2013097487 A JP 2013097487A JP 2013173782 A5 JP2013173782 A5 JP 2013173782A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- pregnan
- pregnane
- oxime
- solvates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (1)
- 3β−フルオロ,5β−プレグナン−20−(R)−オール、
3β−フルオロ,5β−プレグナン−20−(S)−オール、
3β−フルオロ,5α−プレグナン−20−オン、
3α−フルオロ,5α−プレグナン−20−(R)−オール、
3α−フルオロ,5α−プレグナン−20−オンオキシム、および
3β−フルオロ,5α−プレグナン−20−オンオキシム、
または薬学的に許容されるその塩、もしくは溶媒和物の中から選択される化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86065806P | 2006-11-21 | 2006-11-21 | |
US60/860,658 | 2006-11-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009537124A Division JP5386362B2 (ja) | 2006-11-21 | 2007-11-20 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013173782A JP2013173782A (ja) | 2013-09-05 |
JP2013173782A5 true JP2013173782A5 (ja) | 2013-10-17 |
JP5657052B2 JP5657052B2 (ja) | 2015-01-21 |
Family
ID=39429970
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009537124A Expired - Fee Related JP5386362B2 (ja) | 2006-11-21 | 2007-11-20 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097486A Active JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097485A Pending JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097487A Active JP5657052B2 (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2015047791A Pending JP2015147774A (ja) | 2006-11-21 | 2015-03-11 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009537124A Expired - Fee Related JP5386362B2 (ja) | 2006-11-21 | 2007-11-20 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097486A Active JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
JP2013097485A Pending JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015047791A Pending JP2015147774A (ja) | 2006-11-21 | 2015-03-11 | Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Country Status (16)
Country | Link |
---|---|
US (9) | US8580983B2 (ja) |
EP (4) | EP2097437B1 (ja) |
JP (5) | JP5386362B2 (ja) |
AU (1) | AU2007322423C1 (ja) |
BR (2) | BRPI0718945B8 (ja) |
CA (2) | CA2664126C (ja) |
DK (3) | DK2711371T3 (ja) |
ES (3) | ES2607852T3 (ja) |
HU (3) | HUE036410T2 (ja) |
IN (1) | IN2014DN02014A (ja) |
MX (1) | MX2009005335A (ja) |
PL (3) | PL2792681T3 (ja) |
PT (1) | PT2097437E (ja) |
RU (1) | RU2458065C2 (ja) |
SI (1) | SI2097437T1 (ja) |
WO (1) | WO2008063128A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2711371T3 (en) | 2006-11-21 | 2018-04-16 | Asarina Pharma Ab | Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders |
CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
ES2566765T3 (es) | 2010-01-14 | 2016-04-15 | Asarina Pharma Ab | Una composición farmacéutica que contiene 3-beta-hidroxi-5-alfa-pregnan-20-ona con propiedades de almacenamiento y solubilidad mejoradas |
WO2011138460A1 (en) * | 2010-05-07 | 2011-11-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Progesterone receptor antagonists and uses thereof |
US10259839B2 (en) * | 2012-11-28 | 2019-04-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | 3-(4′-substituted)-benzyl-ether derivatives of pregnenolone |
SI3461834T1 (sl) | 2013-03-13 | 2021-11-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi |
MX2016008851A (es) * | 2014-01-29 | 2017-03-23 | Umecrine Cognition Ab | Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica. |
SI3224269T1 (sl) * | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
WO2017007840A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
DE102015120587A1 (de) | 2015-11-26 | 2017-06-01 | Brandenburgische Technische Universität Cottbus-Senftenberg | Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden |
PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
MA46566A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
WO2018075698A1 (en) | 2016-10-18 | 2018-04-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
WO2018147791A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
BR112019015362A2 (pt) | 2017-02-10 | 2020-10-20 | Asarina Pharma Ab | 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico |
MX2020005442A (es) | 2017-11-27 | 2022-03-30 | Umecrine Cognition Ab | FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. |
MX2020010219A (es) | 2018-04-05 | 2020-11-09 | Asarina Pharma Aps | Antagonistas de gaba-a para tratar trastornos por abstinencia de sustancia. |
CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
EP4079307A1 (en) | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
CA3237550A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1463755A (fr) * | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
US3152121A (en) | 1962-03-16 | 1964-10-06 | Upjohn Co | 20-ketals of 3-hydroxy-5 beta-pregnan-20-one |
CH491889A (de) | 1966-10-22 | 1970-06-15 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von Steroiden |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US5234603A (en) | 1991-06-04 | 1993-08-10 | Analytical Development Corporation | Methods employing a zirconium salt for use in wastewater treatment |
DE69435286D1 (de) * | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
NZ282939A (en) * | 1994-02-14 | 1998-08-26 | Cocensys Inc | Androstanes and pregnanes for allosteric modulation of gaba receptors |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
CN1171114A (zh) * | 1994-11-23 | 1998-01-21 | 科斯赛斯公司 | 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系 |
ATE284895T1 (de) * | 1995-06-06 | 2005-01-15 | Euro Celtique Sa | Neuroaktive steroide der androstan- und pregnanreihe |
AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
ATE307592T1 (de) | 1998-03-11 | 2005-11-15 | Torbjoern Backstroem | Epiallopregnanolon zur behandlung von krankheiten des cns |
WO1999052532A1 (en) | 1998-04-14 | 1999-10-21 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
CZ294278B6 (cs) * | 1999-11-25 | 2004-11-10 | Ústav organické chemie a biochemie AV ČR | Neuroaktivní steroidy a způsob jejich přípravy |
GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
FR2831441B1 (fr) | 2001-10-25 | 2003-12-26 | Oreal | Utilisation cosmetique de derives de la dhea |
EP1310258A1 (en) | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Enantiomers of steroids for the enhancement of memory and cognitive function |
SE0104423D0 (sv) * | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
CA2585359C (en) * | 2004-11-18 | 2013-01-08 | Umecrine Ab | Gaba-steroid antagonists and their use for the treatment of cns disorders |
DK2711371T3 (en) | 2006-11-21 | 2018-04-16 | Asarina Pharma Ab | Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders |
WO2011138460A1 (en) | 2010-05-07 | 2011-11-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Progesterone receptor antagonists and uses thereof |
-
2007
- 2007-11-20 DK DK13198584.8T patent/DK2711371T3/en active
- 2007-11-20 EP EP07835459.4A patent/EP2097437B1/en active Active
- 2007-11-20 BR BRPI0718945A patent/BRPI0718945B8/pt active IP Right Grant
- 2007-11-20 EP EP13198608.5A patent/EP2711372A1/en not_active Withdrawn
- 2007-11-20 HU HUE13198584A patent/HUE036410T2/hu unknown
- 2007-11-20 DK DK14154304.1T patent/DK2792681T3/en active
- 2007-11-20 PT PT78354594T patent/PT2097437E/pt unknown
- 2007-11-20 IN IN2014DEN2014 patent/IN2014DN02014A/en unknown
- 2007-11-20 BR BR122013033954A patent/BR122013033954B8/pt not_active IP Right Cessation
- 2007-11-20 US US11/943,555 patent/US8580983B2/en not_active Expired - Fee Related
- 2007-11-20 ES ES14154304.1T patent/ES2607852T3/es active Active
- 2007-11-20 CA CA2664126A patent/CA2664126C/en active Active
- 2007-11-20 DK DK07835459.4T patent/DK2097437T3/en active
- 2007-11-20 MX MX2009005335A patent/MX2009005335A/es active IP Right Grant
- 2007-11-20 ES ES13198584.8T patent/ES2662500T3/es active Active
- 2007-11-20 CA CA2833976A patent/CA2833976C/en active Active
- 2007-11-20 PL PL14154304T patent/PL2792681T3/pl unknown
- 2007-11-20 ES ES07835459.4T patent/ES2543841T3/es active Active
- 2007-11-20 HU HUE14154304A patent/HUE033037T2/hu unknown
- 2007-11-20 PL PL13198584T patent/PL2711371T3/pl unknown
- 2007-11-20 HU HUE07835459A patent/HUE026961T2/en unknown
- 2007-11-20 PL PL07835459T patent/PL2097437T3/pl unknown
- 2007-11-20 WO PCT/SE2007/050876 patent/WO2008063128A1/en active Application Filing
- 2007-11-20 JP JP2009537124A patent/JP5386362B2/ja not_active Expired - Fee Related
- 2007-11-20 RU RU2009107537/04A patent/RU2458065C2/ru active
- 2007-11-20 EP EP13198584.8A patent/EP2711371B1/en not_active Not-in-force
- 2007-11-20 SI SI200731681T patent/SI2097437T1/sl unknown
- 2007-11-20 EP EP14154304.1A patent/EP2792681B1/en not_active Not-in-force
- 2007-11-20 AU AU2007322423A patent/AU2007322423C1/en active Active
-
2012
- 2012-12-17 US US13/716,984 patent/US20130102579A1/en not_active Abandoned
- 2012-12-17 US US13/716,794 patent/US20130102578A1/en not_active Abandoned
-
2013
- 2013-03-07 US US13/787,924 patent/US8853190B2/en active Active
- 2013-03-07 US US13/788,074 patent/US20140011793A1/en not_active Abandoned
- 2013-03-07 US US13/788,006 patent/US20140011792A1/en not_active Abandoned
- 2013-03-22 US US13/848,782 patent/US9200028B2/en active Active
- 2013-05-07 JP JP2013097486A patent/JP5918170B2/ja active Active
- 2013-05-07 JP JP2013097485A patent/JP2013173781A/ja active Pending
- 2013-05-07 JP JP2013097487A patent/JP5657052B2/ja active Active
-
2015
- 2015-03-11 JP JP2015047791A patent/JP2015147774A/ja active Pending
- 2015-07-10 US US14/796,301 patent/US20150315231A1/en not_active Abandoned
- 2015-11-19 US US14/945,575 patent/US20160272670A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013173782A5 (ja) | ||
JP2013173781A5 (ja) | ||
JP2015147774A5 (ja) | ||
NO2024001I1 (no) | Ritlecitinib, or a pharmaceutically acceptable salt thereof | |
JP2016028092A5 (ja) | ||
JP2016065085A5 (ja) | ||
JP2015081257A5 (ja) | ||
JP2012107057A5 (ja) | ||
JP2016502162A5 (ja) | ||
JP2016000169A5 (ja) | ||
JP2015528502A5 (ja) | ||
JP2017137500A5 (ja) | ||
JP2015503422A5 (ja) | ||
JP2015525757A5 (ja) | ||
JP2014156468A5 (ja) | ||
JP2014501485A5 (ja) | ||
JP2015125255A5 (ja) | ||
JP2015053052A5 (ja) | ||
JP2017005051A5 (ja) | ||
JP2017508572A5 (ja) | ||
JP2011170856A5 (ja) | ||
JP2013543797A5 (ja) | ||
JP2015504870A5 (ja) | ||
JP2013253099A5 (ja) | ||
CY1121464T1 (el) | Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας |